[1] GOEDERT M，SPILLANTINI M G. A century of Alzheimer's disease[J] . Science，2006，314 (5800)：777-781. [2] SELKOE D J. Cell biology of protein misfolding：the examples of Alzheimer’s and Parkinson’s diseases[J] . Nat Cell Biol，2004，6（11）：1054-1061. [3] ARISPE N，DIAZ J C，SIMAKOVA O. Aβ ion channels. Prospects for treating Alzheimer's disease with Aβ channel blockers[J] . Biochim Biophys Acta，2007，1768（8）：1952-1965. [4] GILLMORE J D，HAWKINS P N. Drug Insight：emerging therapies for amyloidosis[J] . Nat Clin Pract Nephrol，2006，2(5)：263-270. [5] BACHURIN S O. Medicinal chemistry approaches for the treatment and prevention of Alzheimer’s disease[J] . Med Res Rev，2003，23（1）：48-88. [6] CITRON M. Β-secretase inhibition for the treatment of Alzheimer's disease-promise and challenge[J] . Trends Pharmacol Sci，2004，25（2）：92-97. [7] LI Y M. Gamma-secretase：a catalyst of Alzheimer disease and signal transduction[J] . Mol Interv，2001，1（4）：198-207. [8] LASHUEL H A，HARTLEY D M，BALAKHANEH D，et al. New class of inhibitors of amyloid-β fibril formation[J] . J Biochem，2002，277（45）：42881-42890. [9] HAASS C，SELKOE D J. Soluble protein oligomers in neurodegeneration：lessons from the Alzheimer’s amyloid β-peptide[J] . Nat Rev Mol Cell Bio，2007，8(2)：101-112. [10] KLEIN W L. Aβ toxicity in Alzheimer’s disease：globular oligomers (ADDLs) as new vaccine and drug targets[J] . Neurochem Int，2002，41(5)：345-352. [11] WALSH D M，SELKOE D J. Aβ Oligomers-a decade of discovery[J] . J Neurochem，2007，101(5)：1172-1184. [12] BALLATORE C，VIRGINIA M Y. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders[J] . Nat Rev，2007，8（9）：663-672. [13] ALBERTO G R，MARK A S，GEORGE P，et al. Tau phosphorylation and assembly[J] . Acta Neurobiol Exp，2004，64(11)：33-39. [14] AVILA J，SANTA-MAR A I，P REZ M，et al. Tau phosphorylation，aggregation cell toxicity[J] . J Biomed Biotechnol，2006（3）：74539. [15] FERREIRA A. Tau is essential to β-amyloid-induced neurotoxicity[J] . Proc Natl Acad Sci，2002，99(9)：6364-6369. [16] GONG C X，LIU F，INGE G I，et al. Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer’s disease：A therapeutic target[J] . J Biomed Biotechnol，2006（13）：31825. [17] MAZANETZ M P，FISCHER P M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases[J] . Nat Rev，2007，6（6）：464-479. [18] MANDELKOW E M，MANDELKNOW E. Tau in Alzheimer's disease[J] . Cell Biol，1998，8(11)：425-426. [19] AKITA K，TODA M，HOSOKI Y，et al. Hepayan sulphate proteoglycans interact with neurocan and promote neurite outgrowth from cerebellay granule cells[J] . Bio Chem，2004，383(1)：129-138. [20] BECKER C G，BECKER T. Repellent guidance of regenerating optic axons by chondmifin sulfate glycosaminoglycans in zebrafish[J] . J Neurosci，2002，22(3)：842-853. [21] MACE K，SAXOD R，FEUERSTEIN C，et al. Chondroitin and keratan sulfates have opposing efects on attachment and outgrowth of ventral mesencephalic explants in cuhure[J] . Neurosci Res，2002，70(1)：46-56. [22] VAN HORSSEN J，KLEINNIJENHUIS J，MAASS C N，et al. Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques[J] . Neurobiol Aging，2002，23(4)：537-545. [23] PATEY S J，YATES E A，TURNBULL J E. Novel heparan sulphate analogues：inhibition of β-secretase cleavage of amyloid precursor protein[J] . Biochem Society Transa，2005，33(5)：1116-1118. [24] VAN HORSSEN J，WESSELING P，VAN DEN HEUVEL L P，et al. Heparan sulphate proteoglycans in Alzheimer’s disease and amyloid-related disorders[J] . Lancet Neurol，2003，2(8)：482-492. [25] BOVOLENTA P，ISABEL F E. Nervous system proteoglycans as modulators of neurite outgrowth[J] . Prog Neurobiol，2000，61 (2) ：113-132. [26] GIULIAN DANA，HAVERKAMP L J，JIAHAN Y，et al. The HHQK domain of β-amyloid provides a structural basis for the immunopathology of Alzheimer’s disease[J] . J Biol Chem，1998，273：29719-29726. [27] FRIEDHOFF P，VON BERGEN M，MANDELKNOW E M. Stru- cture of Tau protein and assembly into paired helical filaments[J] . Biochim Biophy Acta，2000，1502 (1) ：122-132. [28] LUO J Y，CHEN Y H，HE R Q. Effect of heparin on aggregation and phosphorylation of human neuronal tau protein[J] . Chin J Biochem Mol Biol，1999，15 (5) ：828-832. [29] CHIRITA C N，KURET J. Evidence for an intermediate in tau filament formation[J] . Biochemistry，2004，43(6)：1704-1714. [30] KING M E，AHUJA V，BINDER L I，et al. Ligand dependent tau filament formation：Implications for Alzheimer's disease progression[J] . Biochemistry，1999，38(45)：14851-14859. [31] GAMBLIN T C，KING M E，DAWSON H，et al. In vitro polymerization of tau protein monitored by laser light scattering：method and application to the study of FTDP-17 mutants[J] . Biochemistry，2000，39(20)：6136-6144. [32] CARLSON S W，BRANDEN M，VOSS K，et al. A complex mechanism for inducer mediated tau polymerization[J] . Biochemistry，2007，46(30)：8838-8849. [33] MOHAND-OUIDIR O，EMMANUEL P，MARIE-EMMANUELLE K，et al. Structure activity studies of heparan mimetic polyanions for anti-prion therapies[J] . Biochem Biophys Res Commun，2007，363(1)：95-100. [34] HONG Z，JIN Y，MARK S. Inhibition of amyloidosis using low-molecular-weight heparins[J] . Mol Med，2001，7(8)：517-522. [35] LEVEUGLE B，DING W，LAURENCE F，et al. Heparin oligosaccharides that pass the blood-brain barrier inhibit β-amyloid precursor protein secretion and heparin binding to β-amyloid peptide[J] . J Neurochem，1998，70 (2) ：736-744. [36] FRASER P E，DARABIE A A，MCLAURIN J. Amyloid-β interactions with chondroitin sulfate-derived monosaccharides and disaccharides[J] . J Biochem，2001，276：6412-6419. [37] ROSEA M，DUDASB B，CORNELLI U，et al. Glycosaminoglycan C3 protects against AF64A-induced cholinotoxicity in a dose-dependent and time-dependent manner[J] . Brain Res，2004，1015(1-2)：96-102. [38] WALZER M，LORENS S，HEJNA M，et al. Low molecular weight glycosaminoglycan blockade of β-amyloid induced neuropathology[J] . Eur J Pharmacol，2002，445(3)：211-220. [39] MCLAURIN J，KIERSTEAD M E，BROWN M E，et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model[J] . Nat Med，2006，12(7)：801-808.